國立高雄大學圖資館 |

登入

回首頁

Infectious diseases drug delivery systems

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Infectious diseases drug delivery systemsedited by Ranjita Shegokar, Yashwant Pathak.
其他作者:	Shegokar, Ranjita.
出版者:	Cham :Springer International Publishing :2023.
面頁冊數:	1 online resource (x, 439 p.) :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	Communicable diseasesChemotherapy.
電子資源:	https://doi.org/10.1007/978-3-031-20521-7
ISBN:	9783031205217$q(electronic bk.)

Infectious diseases drug delivery systems
Infectious diseases drug delivery systems[electronic resource] /edited by Ranjita Shegokar, Yashwant Pathak. - Cham :Springer International Publishing :2023. - 1 online resource (x, 439 p.) :ill., digital ;24 cm.

New drugs in synthesis research for Malaria -- New drugs in synthesis research for TB -- New drugs in synthesis viral -- Nanotechnology in Malaria diagnosis -- Nanotechnology in TB diagnosis -- Nanotechnology based vaccination Malaria -- Nanotechnology based vaccination TB -- Disease models in Malaria research -- Disease models in TB research -- Disease models in Viral research -- Viral diseases- cellular understanding of disease : Vaccine development -- Pneumonia- infection -- bacterial pnuemonia -- Lipid based DDS in pneumonia -- hepatitis -- Recent Developments in the Treatment of Bacterial Meningitis -- Bacterial Urinary Tract Infections -- E.coli.

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY) Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems Infectious diseases are the world's greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is "worse" or "better" than in past. The answer is probably "worse", may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an "emerging" disease, and a growing number have made watch lists and headlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.

ISBN: 9783031205217$q(electronic bk.)

Standard No.: 10.1007/978-3-031-20521-7doiSubjects--Topical Terms:

943865
Communicable diseases
--Chemotherapy.

LC Class. No.: RC111

Dewey Class. No.: 616.90461

Infectious diseases drug delivery systems
LDR:04401nmm a2200325 a 4500 001 637431
003 DE-He213
005 20230518173123.0
006 m d
007 cr nn 008maaau
008 230921s2023 sz s 0 eng d
020 $a 9783031205217$q(electronic bk.)
020 $a 9783031205200$q(paper)
024 7 $a 10.1007/978-3-031-20521-7 $2 doi
035 $a 978-3-031-20521-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC111
072 7 $a TCB $2 bicssc
072 7 $a SCI010000 $2 bisacsh
072 7 $a TCB $2 thema
082 0 4 $a 616.90461 $2 23
090 $a RC111 $b .I43 2023
245 0 0 $a Infectious diseases drug delivery systems $h [electronic resource] / $c edited by Ranjita Shegokar, Yashwant Pathak.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a 1 online resource (x, 439 p.) : $b ill., digital ; $c 24 cm.
505 0 $a New drugs in synthesis research for Malaria -- New drugs in synthesis research for TB -- New drugs in synthesis viral -- Nanotechnology in Malaria diagnosis -- Nanotechnology in TB diagnosis -- Nanotechnology based vaccination Malaria -- Nanotechnology based vaccination TB -- Disease models in Malaria research -- Disease models in TB research -- Disease models in Viral research -- Viral diseases- cellular understanding of disease : Vaccine development -- Pneumonia- infection -- bacterial pnuemonia -- Lipid based DDS in pneumonia -- hepatitis -- Recent Developments in the Treatment of Bacterial Meningitis -- Bacterial Urinary Tract Infections -- E.coli.
520 $a The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY) Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems Infectious diseases are the world's greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is "worse" or "better" than in past. The answer is probably "worse", may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an "emerging" disease, and a growing number have made watch lists and headlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.
650 0 $a Communicable diseases $x Chemotherapy. $3 943865
650 0 $a Drug delivery systems. $3 196465
650 0 $a Disability evaluation. $3 317396
650 0 $a Quality of life. $3 208442
650 1 4 $a Drug Delivery. $3 911847
650 2 4 $a Diseases. $3 276053
650 2 4 $a Pharmacology. $3 218135
650 2 4 $a Epidemiology. $3 191577
650 2 4 $a Pharmaceutics. $3 913065
700 1 $a Shegokar, Ranjita. $3 797037
700 1 $a Pathak, Yashwant. $3 520484
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-20521-7
950 $a Biomedical and Life Sciences (SpringerNature-11642)